Urology;Urologie

Revue Medicale Suisse

Volumn 6, Issue 232, 2010, Pages 145-149

  Wisard, Marc ^a   Pescia, Graziano ^b  

^a Centre de Procreation Medicalement Assistee et d'Endocrinologie Gynecologique Lausanne   (Switzerland)

^b Aurigen   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; PROSTATE SPECIFIC ANTIGEN; PROTEIN PCA3; SELENIUM; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CANCER PREVENTION; CANCER SURVIVAL; GENETIC ANALYSIS; HUMAN; LAPAROSCOPY; PROSTATE CANCER; REVIEW; TUMOR BIOPSY;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 76749091107     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. ** Schröder F, Hugosson J, Roobol M, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
2. ** Andriole G, Crawford D, Grubb R, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
3. ** Prostate-specific antigen best practice statement: Update 2009. www.auanet.org
4. Loeb S, Roehl KA, Antenor JVA, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006;67:316-20.
5. Larre S, Azzouzi AR, Cormier L, et al. Comment le dépistage du cancer de la prostate est-il perçu par les hommes de 50 à 70 ans? Progrès en Urologie 2007;17:939-42.
6. Abrahamson PA, Artibani W, Chapple CR, Wirth M. European association of urology statement on screening for prostate cancer. Eur J Urol 2009;56:270-1.
7. Grill M. Alarm und Fehlalarm. Der Spiegel 2009;124.
8. Bratt O. Hereditary prostate cancer: Clinical aspects. Urol 2002;168:906-13.
9. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009;115:3879-86.
10. Chun FK, de la Taille A, van Poppel H, et al. Prostate cancer Gene 3 (PCA3): Development and internal validation of a novel biopsy normogram. Eur Urol 2009;epub ahead of print.
11. ** Eggener SE, Guilloneau B. Laparoscopic radical prostatectomy: Ten years later, time for evidence-based foundation. Eur Uol 2008;54:4-7.
12. ** Ficarra V, Novara G, Artibani W, et al. Retropubic, laparoscopic and robot-assisted radical prostatectomy: A systemic review and cumulative analysis of comparative studies. Eur Urol 2009;55:1037-63.
13. Schroeck FR, Krupski TL, Sun D, et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008;54:785-93.
14. ** Mottet N, Irani J. Place de la surveillance active dans le cancer de la prostate: présentation du protocole français. www.urofrance.org/nc/medecins/base-urofrance/article/
15. Klotz L. Active surveillance for prostate cancer: For whom. J Clin Oncol 2005;23:8165-9.
16. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006;24:46-50.
17. * Eggener SE, Mueller A, Berglund RK, et al. A multiinstitutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009;181:1635-41.
18. * Shappley WV, Kenfield SA, Kasperzyk JL, et al. Prospective study determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:4980-5.
19. Duffield AS, Lee TK, Myamoto H, et al. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009;182:2274-8.
20. Van den Bergh RC, Essink-Bot ML, Roobol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009;115:3868-78.
21. Hegarty JM, Wallace M, Comber H. Uncertainly and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland. Am J Mens Health 2008;2:133-42.
22. ** Colli JL, Amling CL: Chemopreventtion of prostate cancer: What can be recommanded to patients? Current Urology Reports. May 2009;3:10:165-171.
23. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamine E on risk of prostate cancer and other cancers: The Selenium and Vitamine E Cancer Prevention Trial (Select). JAMA 2009;301:39-51.
24. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: The Physician's Health Study II randomized controlled trial. JAMA 2009;30:301:52-62.
25. Thorpe JF, Jain S, Marczylo TH, et al. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 2007;89:207-11.